[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] My list:
1) First line chemo/IO combos, esp KN189 & KN407
2) Durva consolidation - > major OS benefit in st 3 NSCLC
3) 1L IO monotherapy for PD-L1 high (but NOT 1-49%)
4) next gen TKIs upfront (esp CNS activity)
5) new targets (ROS1, MET, RET, even KRAS) - > broad NGS testing now